Cargando…
Quantification and reduction of cross-vendor variation in multicenter DWI MR imaging: results of the Cancer Core Europe imaging task force
OBJECTIVES: In the Cancer Core Europe Consortium (CCE), standardized biomarkers are required for therapy monitoring oncologic multicenter clinical trials. Multiparametric functional MRI and particularly diffusion-weighted MRI offer evident advantages for noninvasive characterization of tumor viabili...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705481/ https://www.ncbi.nlm.nih.gov/pubmed/35678860 http://dx.doi.org/10.1007/s00330-022-08880-7 |
_version_ | 1784840293521031168 |
---|---|
author | Sedlaczek, Oliver Lukas Kleesiek, Jens Gallagher, Ferdia A. Murray, Jacob Prinz, Sebastian Perez-Lopez, Raquel Sala, Evia Caramella, Caroline Diffetock, Sebastian Lassau, Nathalie Priest, Andrew N. Suzuki, Chikako Vargas, Roberto Giandini, Tommaso Vaiani, Marta Messina, Antonella Blomqvist, Lennart K. Beets-Tan, Regina G. H. Oberrauch, Petra Schlemmer, Heinz-Peter Bach, Michael |
author_facet | Sedlaczek, Oliver Lukas Kleesiek, Jens Gallagher, Ferdia A. Murray, Jacob Prinz, Sebastian Perez-Lopez, Raquel Sala, Evia Caramella, Caroline Diffetock, Sebastian Lassau, Nathalie Priest, Andrew N. Suzuki, Chikako Vargas, Roberto Giandini, Tommaso Vaiani, Marta Messina, Antonella Blomqvist, Lennart K. Beets-Tan, Regina G. H. Oberrauch, Petra Schlemmer, Heinz-Peter Bach, Michael |
author_sort | Sedlaczek, Oliver Lukas |
collection | PubMed |
description | OBJECTIVES: In the Cancer Core Europe Consortium (CCE), standardized biomarkers are required for therapy monitoring oncologic multicenter clinical trials. Multiparametric functional MRI and particularly diffusion-weighted MRI offer evident advantages for noninvasive characterization of tumor viability compared to CT and RECIST. A quantification of the inter- and intraindividual variation occurring in this setting using different hardware is missing. In this study, the MRI protocol including DWI was standardized and the residual variability of measurement parameters quantified. METHODS: Phantom and volunteer measurements (single-shot T2w and DW-EPI) were performed at the seven CCE sites using the MR hardware produced by three different vendors. Repeated measurements were performed at the sites and across the sites including a traveling volunteer, comparing qualitative and quantitative ROI-based results including an explorative radiomics analysis. RESULTS: For DWI/ADC phantom measurements using a central post-processing algorithm, the maximum deviation could be decreased to 2%. However, there is no significant difference compared to a decentralized ADC value calculation at the respective MRI devices. In volunteers, the measurement variation in 2 repeated scans did not exceed 11% for ADC and is below 20% for single-shot T2w in systematic liver ROIs. The measurement variation between sites amounted to 20% for ADC and < 25% for single-shot T2w. Explorative radiomics classification experiments yield better results for ADC than for single-shot T2w. CONCLUSION: Harmonization of MR acquisition and post-processing parameters results in acceptable standard deviations for MR/DW imaging. MRI could be the tool in oncologic multicenter trials to overcome the limitations of RECIST-based response evaluation. KEY POINTS: • Harmonizing acquisition parameters and post-processing homogenization, standardized protocols result in acceptable standard deviations for multicenter MR–DWI studies. • Total measurement variation does not to exceed 11% for ADC in repeated measurements in repeated MR acquisitions, and below 20% for an identical volunteer travelling between sites. • Radiomic classification experiments were able to identify stable features allowing for reliable discrimination of different physiological tissue samples, even when using heterogeneous imaging data. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00330-022-08880-7. |
format | Online Article Text |
id | pubmed-9705481 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-97054812022-11-30 Quantification and reduction of cross-vendor variation in multicenter DWI MR imaging: results of the Cancer Core Europe imaging task force Sedlaczek, Oliver Lukas Kleesiek, Jens Gallagher, Ferdia A. Murray, Jacob Prinz, Sebastian Perez-Lopez, Raquel Sala, Evia Caramella, Caroline Diffetock, Sebastian Lassau, Nathalie Priest, Andrew N. Suzuki, Chikako Vargas, Roberto Giandini, Tommaso Vaiani, Marta Messina, Antonella Blomqvist, Lennart K. Beets-Tan, Regina G. H. Oberrauch, Petra Schlemmer, Heinz-Peter Bach, Michael Eur Radiol Magnetic Resonance OBJECTIVES: In the Cancer Core Europe Consortium (CCE), standardized biomarkers are required for therapy monitoring oncologic multicenter clinical trials. Multiparametric functional MRI and particularly diffusion-weighted MRI offer evident advantages for noninvasive characterization of tumor viability compared to CT and RECIST. A quantification of the inter- and intraindividual variation occurring in this setting using different hardware is missing. In this study, the MRI protocol including DWI was standardized and the residual variability of measurement parameters quantified. METHODS: Phantom and volunteer measurements (single-shot T2w and DW-EPI) were performed at the seven CCE sites using the MR hardware produced by three different vendors. Repeated measurements were performed at the sites and across the sites including a traveling volunteer, comparing qualitative and quantitative ROI-based results including an explorative radiomics analysis. RESULTS: For DWI/ADC phantom measurements using a central post-processing algorithm, the maximum deviation could be decreased to 2%. However, there is no significant difference compared to a decentralized ADC value calculation at the respective MRI devices. In volunteers, the measurement variation in 2 repeated scans did not exceed 11% for ADC and is below 20% for single-shot T2w in systematic liver ROIs. The measurement variation between sites amounted to 20% for ADC and < 25% for single-shot T2w. Explorative radiomics classification experiments yield better results for ADC than for single-shot T2w. CONCLUSION: Harmonization of MR acquisition and post-processing parameters results in acceptable standard deviations for MR/DW imaging. MRI could be the tool in oncologic multicenter trials to overcome the limitations of RECIST-based response evaluation. KEY POINTS: • Harmonizing acquisition parameters and post-processing homogenization, standardized protocols result in acceptable standard deviations for multicenter MR–DWI studies. • Total measurement variation does not to exceed 11% for ADC in repeated measurements in repeated MR acquisitions, and below 20% for an identical volunteer travelling between sites. • Radiomic classification experiments were able to identify stable features allowing for reliable discrimination of different physiological tissue samples, even when using heterogeneous imaging data. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00330-022-08880-7. Springer Berlin Heidelberg 2022-06-09 2022 /pmc/articles/PMC9705481/ /pubmed/35678860 http://dx.doi.org/10.1007/s00330-022-08880-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Magnetic Resonance Sedlaczek, Oliver Lukas Kleesiek, Jens Gallagher, Ferdia A. Murray, Jacob Prinz, Sebastian Perez-Lopez, Raquel Sala, Evia Caramella, Caroline Diffetock, Sebastian Lassau, Nathalie Priest, Andrew N. Suzuki, Chikako Vargas, Roberto Giandini, Tommaso Vaiani, Marta Messina, Antonella Blomqvist, Lennart K. Beets-Tan, Regina G. H. Oberrauch, Petra Schlemmer, Heinz-Peter Bach, Michael Quantification and reduction of cross-vendor variation in multicenter DWI MR imaging: results of the Cancer Core Europe imaging task force |
title | Quantification and reduction of cross-vendor variation in multicenter DWI MR imaging: results of the Cancer Core Europe imaging task force |
title_full | Quantification and reduction of cross-vendor variation in multicenter DWI MR imaging: results of the Cancer Core Europe imaging task force |
title_fullStr | Quantification and reduction of cross-vendor variation in multicenter DWI MR imaging: results of the Cancer Core Europe imaging task force |
title_full_unstemmed | Quantification and reduction of cross-vendor variation in multicenter DWI MR imaging: results of the Cancer Core Europe imaging task force |
title_short | Quantification and reduction of cross-vendor variation in multicenter DWI MR imaging: results of the Cancer Core Europe imaging task force |
title_sort | quantification and reduction of cross-vendor variation in multicenter dwi mr imaging: results of the cancer core europe imaging task force |
topic | Magnetic Resonance |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705481/ https://www.ncbi.nlm.nih.gov/pubmed/35678860 http://dx.doi.org/10.1007/s00330-022-08880-7 |
work_keys_str_mv | AT sedlaczekoliverlukas quantificationandreductionofcrossvendorvariationinmulticenterdwimrimagingresultsofthecancercoreeuropeimagingtaskforce AT kleesiekjens quantificationandreductionofcrossvendorvariationinmulticenterdwimrimagingresultsofthecancercoreeuropeimagingtaskforce AT gallagherferdiaa quantificationandreductionofcrossvendorvariationinmulticenterdwimrimagingresultsofthecancercoreeuropeimagingtaskforce AT murrayjacob quantificationandreductionofcrossvendorvariationinmulticenterdwimrimagingresultsofthecancercoreeuropeimagingtaskforce AT prinzsebastian quantificationandreductionofcrossvendorvariationinmulticenterdwimrimagingresultsofthecancercoreeuropeimagingtaskforce AT perezlopezraquel quantificationandreductionofcrossvendorvariationinmulticenterdwimrimagingresultsofthecancercoreeuropeimagingtaskforce AT salaevia quantificationandreductionofcrossvendorvariationinmulticenterdwimrimagingresultsofthecancercoreeuropeimagingtaskforce AT caramellacaroline quantificationandreductionofcrossvendorvariationinmulticenterdwimrimagingresultsofthecancercoreeuropeimagingtaskforce AT diffetocksebastian quantificationandreductionofcrossvendorvariationinmulticenterdwimrimagingresultsofthecancercoreeuropeimagingtaskforce AT lassaunathalie quantificationandreductionofcrossvendorvariationinmulticenterdwimrimagingresultsofthecancercoreeuropeimagingtaskforce AT priestandrewn quantificationandreductionofcrossvendorvariationinmulticenterdwimrimagingresultsofthecancercoreeuropeimagingtaskforce AT suzukichikako quantificationandreductionofcrossvendorvariationinmulticenterdwimrimagingresultsofthecancercoreeuropeimagingtaskforce AT vargasroberto quantificationandreductionofcrossvendorvariationinmulticenterdwimrimagingresultsofthecancercoreeuropeimagingtaskforce AT giandinitommaso quantificationandreductionofcrossvendorvariationinmulticenterdwimrimagingresultsofthecancercoreeuropeimagingtaskforce AT vaianimarta quantificationandreductionofcrossvendorvariationinmulticenterdwimrimagingresultsofthecancercoreeuropeimagingtaskforce AT messinaantonella quantificationandreductionofcrossvendorvariationinmulticenterdwimrimagingresultsofthecancercoreeuropeimagingtaskforce AT blomqvistlennartk quantificationandreductionofcrossvendorvariationinmulticenterdwimrimagingresultsofthecancercoreeuropeimagingtaskforce AT beetstanreginagh quantificationandreductionofcrossvendorvariationinmulticenterdwimrimagingresultsofthecancercoreeuropeimagingtaskforce AT oberrauchpetra quantificationandreductionofcrossvendorvariationinmulticenterdwimrimagingresultsofthecancercoreeuropeimagingtaskforce AT schlemmerheinzpeter quantificationandreductionofcrossvendorvariationinmulticenterdwimrimagingresultsofthecancercoreeuropeimagingtaskforce AT bachmichael quantificationandreductionofcrossvendorvariationinmulticenterdwimrimagingresultsofthecancercoreeuropeimagingtaskforce AT quantificationandreductionofcrossvendorvariationinmulticenterdwimrimagingresultsofthecancercoreeuropeimagingtaskforce |